Abstract:BACKGROUND:Weight-based dosing strategy is still challenging due to poor awareness and adherence. It is necessary to let clinicians know of the latest developments in this respect and the correct circumstances in which weight-based dosing is of clinical relevance.METHODS:A literature search was conducted using PubMed.RESULTS:Clinical indications, physiological factors, and types of medication may determine the applicability of weight-based dosing. In some cases, the weight effect may be minimal or the proper dosage can only be determined when weight is combined with other factors. Medications within similar therapeutic or structural class (eg, anticoagulants, antitumor necrosis factor medications, P2Y12-receptor antagonists, and anti-epidermal growth factor receptor antibodies) may exhibit differences in requirements on weight-based dosing. In some cases, weight-based dosing is superior to currently recommended fixed-dose regimen in adult patients (eg, hydrocortisone, vancomycin, linezolid, and aprotinin). On the contrary, fixed dosing is noninferior to or even better than currently recommended weight-based regimen in adult patients in some cases (eg, cyclosporine microemulsion, recombinant activated Factor VII, and epoetin α). Ideal body-weight-based dosing may be superior to the currently recommended total body-weight-based regimen (eg, atracurium and rocuronium). For dosing in pediatrics, whether weight-based dosing is better than body surface-area-based dosing is dependent on the particular medication (eg, methotrexate, prednisone, prednisolone, zidovudine, didanosine, growth hormone, and 13-cis-retinoic acid). Age-based dosing strategy is better than weight-based dosing in some cases (eg, intravenous busulfan and dalteparin). Dosing guided by pharmacogenetic testing did not show pharmacoeconomic advantage over weight-adjusted dosing of 6-mercaptopurine. The common viewpoint (ie, pediatric patients should be dosed on the basis of body weight) is not always correct. Effective weight-based dosing interventions include standardization of weight estimation, documentation and dosing determination, dosing chart, dosing protocol, order set, pharmacist participation, technological information, and educational measures.CONCLUSION:Although dosing methods are specified in prescribing information for each drug and there are no principal pros and cons to be elaborated, this review of weight-based dosing strategy will enrich the knowledge of medication administration from the perspectives of safety, efficacy, and pharmacoeconomics, and will also provide research opportunities in clinical practice. Clinicians should be familiar with dosage and administration of the medication to be prescribed as well as the latest developments.

Dosing Adjustments in Cases of Altered Plasma Protein Binding are Most Needed for Drugs with a Volume of Distribution Below 1.3 L/kg

Weight-based Dosing in Medication Use: What Should We Know?

No Bene Fi T of Higher Protein Dosing in Critically Ill Patients: a Systematic Review and Meta-Analysis of Randomized Controlled Trials

Effectiveness of Pharmacist Dosing Adjustment for Critically Ill Patients Receiving Continuous Renal Replacement Therapy: a Comparative Study.

Facing the Facts of Altered Plasma Protein Binding: Do Current Models Correctly Predict Changes in Fraction Unbound in Special Populations?

Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions

Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment

Impact of pH on Plasma Protein Binding in Equilibrium Dialysis

“Getting the Dose Right”—Revisiting the Topic With Focus on Biologic Agents

Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?

The Significance of Plasma Protein Binding on the Fetal/Maternal Distribution of Drugs at Steady-State

Protein Binding in Translational Antimicrobial Development-Focus on Interspecies Differences

On the Way to More Convenient Description of Drug-Plasma Protein Binding

Applied pharmacokinetics to improve pharmacotherapy in neonatal and paediatric intensive care units: focus on correct dose selection

Total and Free Blood and Plasma Concentration Changes in Pregnancy for Medicines Highly Bound to Plasma Proteins: Application of Physiologically Based Pharmacokinetic Modelling to Understand the Impact on Efficacy

New Approaches to the Use of Pharmacokinetics in Toxicology and Drug Development

Age-Related Changes in Vancomycin Protein Binding: Is it Time to Take it Seriously?

Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis

Doses Evaluated in Clinical Pharmacology Studies Investigating the Effect of Intrinsic and Extrinsic Factors on PK and Safety: Case Examples from Approved Drug Development Programs

Drug Dosage in the Elderly

Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule–Related Therapeutic Modalities